Paragon Development Systems (PDS) was recognized recently by the Massachusetts Institute of Technology (MIT) for their contributions to biomedical research and technology innovation through the MIT linQ program (formerly known as the Madrid-MIT M+Visión Consortium).
At the recent event in Madrid, Spain, 120 members of the biomedical technology innovation community, including public leaders, engineers, entrepreneurs, scientists, and clinicians gathered to celebrate five years of the M+Visión Consortium. The Consortium leadership recognized PDS’s on-going support of biomedical technology innovation through contributions to its Catalyst and IMPACT programs.
These programs help emerging biomedical technology innovators and entrepreneurs identify unmet healthcare needs, and provide them support as they develop practical solutions. PDS and President and CEO Dr. Asif Naseem have played a key role in supporting these programs and mentoring participants.
“PDS has been and will remain a valuable partner in our effort to transform the way healthcare technology is developed,” said Dr. Martha Gray, Director of MIT linQ. “We look forward to our continued collaboration, which will not only help to launch important new technologies but more importantly, will continue to inspire change in the way innovators think and work to improve their healthcare impact.”
“We are excited to have the opportunity to contribute to this important work and to collaborate with such a prestigious institution,” said Dr. Naseem. “We look forward to a continued relationship, and the impact this partnership will have on the healthcare and IT industries.”
Company:
Paragon Development Systems (PDS)
